TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05413603

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic focus Shock wave lithotripsy
Description: successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic focus Shock wave lithotripsy
Description: successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopic focus Shock wave lithotripsy
Description: successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopic focus Shock wave lithotripsy
Description: successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
Study: NCT04961359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
Study: NCT05298241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-grip Strength Game
Description: Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
Study: NCT06380283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Use of a virtual reality headset during pediatric dental care
Study: NCT05790590

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Double low dose CT
Description: Simultaneous reduction of both radiation dose and contrast media dose

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose CT
Description: CT with standard radiation dose and contrast media dose
Study: NCT05644496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
Description: Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
Study: NCT04913922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: s.c. 75 mg/m2 BSA for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: 80-160mg i.v.
Study: NCT06157476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretch-shortening exercise
Description: The SSC-Ex program was conducted for 35 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise program
Description: The standard exercise program lasted for 35 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.
Study: NCT06031285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Perioperative Sinitilimab, bevacizumab biosimilar and TACE-HAIC
Study: NCT05414188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation runs for 60 minutes per session. The pulmonary rehabilitation program is based on a comprehensive approach, not simply providing regular exercise. And it includes patient education, active encouragement, and psychological support by investigators. Exercise is performed more than twice a week. Each session is performed for 60 minutes and includes breathing exercises, low to medium-intensity aerobic exercises, and muscle exercises under the guidance of a investigator. After radiation therapy is completed, investigators will recommend that patients perform pulmonary rehabilitation at home more than twice a week and for 60 minutes or more. The patients will record whether and when exercise is performed every day in the diary for pulmonary rehabilitation.
Study: NCT05387642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo
Description: Single dose with a washout period between doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo
Description: Single dose with a washout period between doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PRAX-114, 20 mg PRAX-114, and Placebo
Description: Single dose with a washout period between doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PRAX-114 or 20 mg PRAX-114
Description: Once daily oral treatment for 28 days
Study: NCT05026554

Intervention type: GENETIC
Intervention: Tape stripping
Description: Optional genetic analysis for chronic hand eczema

Intervention type: GENETIC
Intervention: Tape stripping
Description: Optional genetic analysis for chronic hand eczema

Intervention type: GENETIC
Intervention: Tape stripping
Description: Optional genetic analysis for chronic hand eczema
Study: NCT06122558

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
Study: NCT05407883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School traffic warden programme
Description: Trained school traffic wardens placed at school crossing points to help children cross
Study: NCT05441189

Intervention type: PROCEDURE
Intervention: Resection
Description: radical R0 resection of pancreatic adenocarcinoma

Intervention type: PROCEDURE
Intervention: Resection
Description: radical R0 resection of pancreatic adenocarcinoma
Study: NCT05295407

Intervention type: GENETIC
Intervention: Genetic Assessment
Description: The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
Study: NCT04469127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177-DOTAGA-IAC
Description: Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.
Study: NCT05714345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study: NCT04765904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 1)Dry with cotton to affected tooth surfaces 2) Apply the SDF material 3)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up
Study: NCT05714345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-501A
Description: ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-501A
Description: ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
Study: NCT04869007

Intervention type: DEVICE
Intervention: hysterosonography
Description: Isthmocele mesured by hysterosonography before ART procedure

Intervention type: DEVICE
Intervention: hysterosonography
Description: Isthmocele mesured by hysterosonography before ART procedure
Study: NCT05881252

Intervention type: PROCEDURE
Intervention: Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension
Description: Patients are treated for hypertension if SBP \>= 160 mmHg.

Intervention type: PROCEDURE
Intervention: Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension
Description: Patients are treated for hypertension if SBP \>= 180 mmHg.
Study: NCT05086276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: Active Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05280990

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mHBS
Description: Preoperative FLRF assessment using 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT/MRI volumetry
Description: Preoperative FLRF assessment using CT/MRI volumetry
Study: NCT04832737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADDapt Ability Framework
Description: 12 week individual therapeutic coaching intervention
Study: NCT05252338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVSQIV
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVSQIV
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study: NCT06391411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg)
Description: In this three-arm randomized, controlled trial, with one arm represented by healthy subjects, eligible participants were randomly divided into two groups. Fifteen patients were randomly allocated to the intervention group and received, for 6 months, intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen and daily supplementation with a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg). The other fifteen patients was assigned to the control group and only received the intravitreal anti-VEGF treatment at a fixed regimen for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-VEGF treatment
Description: Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-VEGF treatment
Description: Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months
Study: NCT06361290

Intervention type: OTHER
Intervention: Data collection from hospital medical records
Description: Data collection from hospital medical records of patients concerning the 5 years following the resection of the tumor.
Study: NCT05248789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: OH2: Oncolytic Type 2 Herpes Simplex Virus
Study: NCT05187221

Intervention type: BEHAVIORAL
Intervention: CVS Group
Description: CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
Study: NCT06326957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SELF-BREATHE
Description: SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.
Study: NCT04632485

Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: Carotid artery ultrasound exam. US imaging will include complete clinical carotid ultrasound examination (B-mode, Doppler and color-flow modes), clinical strain and shear wave imaging study, backscattered and beam-steered radiofrequency (RF) data acquisition using research mode, and reference phantom RF data acquisition.

Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: Carotid artery ultrasound exam. US imaging will include complete clinical carotid ultrasound examination (B-mode, Doppler and color-flow modes), clinical strain and shear wave imaging study, backscattered and beam-steered radiofrequency (RF) data acquisition using research mode, and reference phantom RF data acquisition.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Head and Neck MRI exam with contrast

Intervention type: OTHER
Intervention: Neurocognitive testing
Description: Harmonization battery to assess executive function/attention, speeded psychomotor, verbal, and nonverbal memory, language, and visuospatial skills

Intervention type: DEVICE
Intervention: Transcranial Doppler (TCD)
Description: Use of a TCD system to monitor right and left middle cerebral artery Doppler waveforms in the volunteer for 60 minutes

Intervention type: DEVICE
Intervention: Pulse Wave Doppler
Description: Pulse wave Doppler will be used to acquire a Doppler waveform in the right common carotid artery and the right femoral artery
Study: NCT06472921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Butylphthalide treatment initiation time
Description: Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\&lt;3 hours) and a late initiation group (3-6 hours).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Butylphthalide treatment initiation time
Description: Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\&lt;3 hours) and a late initiation group (3-6 hours).
Study: NCT06294561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole+TGRX-326
Description: healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Itraconazole 200 mg with TGRX-326 60 mg orally on day 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz+TGRX-326
Description: healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Efavirenz 600 mg with TGRX-326 60 mg orally on day 20
Study: NCT05238623

Intervention type: DIAGNOSTIC_TEST
Intervention: additional EIT Measurement
Description: Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
Study: NCT04869293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypnosis 3D virtual reality headset
Description: 3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
Study: NCT05089253

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: The subject will be in the supine position and receive dry needling. The first point will be at the medial femoral condyle of the knee joint line in vastus medialis muscles. The second point will be at the lateral femoral condyle of the knee joint line in vastus lateralis muscles. The third point will be above the base of the patella in the rectus femoris muscle. The fourth point will be 2cm above the third point in rectus femoris muscles. These four points were the most common places of trigger point at quadriceps muscles. Dry needling is affected on A-delta fibers. Therefore when superficial dry needling with a noxious stimulation leads to stimulation on A-delta fibers, the excitation remains almost 72 hours and gradually decreases.~The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks.
Study: NCT06228976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based, smoking cessation focused text messages.
Description: Participants will receive mindfulness-based, smoking cessation focused text messages everyday for 12 weeks.
Study: NCT05089253

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tapping
Description: The subject will be in the supine position and receive Kinesio taping. The Kinesio tape application with no tension one Y strip with a length of 20 cm, an anchor of 2 cm.~The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks.
Study: NCT06439459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction transplantation
Description: Stromal vascular fraction was extracted from subcutaneous fat harvested from either the abdomen or the posterior inner thigh region. The SVF cell-pellet was washed and was adjusted to 2×10\^6 cells/mL. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares.~The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg. This procedure was repeated until adequate skin area was achieved for subsequent facial restoration surgery.
Study: NCT06228976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational messages
Description: Text messages focus on the health risks of smoking and secondhand smoking, once everyday for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control messages
Description: Text messages focus on the general healthy lifestyle, once everyday for 12 weeks.
Study: NCT05940428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG712
Description: ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
Study: NCT04612933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group video consultations
Description: All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment.
Study: NCT05578131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high flow nasal oxygen
Description: In the intervention group, pre-oxygenation was provided using HFNO via Optiflow THRIVE™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) until SpO2 on pulse oximetry was \> 95% and for at least 3 min. A flow of 0.5 l/kg/min-1 was used until induction agents had been administered, and then increased to 2 l/kg/min-1. Nasal oxygenation was continued without ventilation of the lungs while waiting for neuromuscular blockade, and during placing, replacing or repositioning the airway. Anaesthetists were free to carry out bag-mask ventilation of the lungs if they considered this necessary to maintain safe oxygen saturations. After securing the airway, the patient was connected to a circle circuit primed with 100% oxygen and the FIO2 was continued at 100% for a period of at least five more minutes. Relevant times were recorded, including start of pre-oxygenation and start of induction of anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: face mask
Description: In the control group, pre-oxygenation was provided using 100% oxygen via a sealed facemask and a circle-absorber anaesthetic circuit primed with 100% oxygen by installing a ventilation bag to the mouthpiece filter and ventilating the circuit with 100% oxygen. Anaesthetists were free to carry out bag-mask ventilation of the lungs once induction medications had been administered.
Study: NCT06424405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: titration procedure for MAD treatment
Description: The OSAHS patients referred for MAD treatment will experience either the objective titration procedure or the subjective titration procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: titration procedure for MAD treatment
Description: The OSAHS patients referred for MAD treatment will experience either the objective titration procedure or the subjective titration procedure.